EXEL Exelixis PE ratio, current and historical analysis
As at Apr 2, 2025, the EXEL stock has a PE ratio of 20.58. This is based on the current EPS of $1.8 and the stock price of $37.04 per share. A decrease of 10% has been recorded in the P/E ratio compared to the average of 22.8 of the last 4 quarters.
EXEL PE ratio history
The mean historical PE ratio of Exelixis over the last eight years is 56.04. The current 20.58 PE ratio is 63% below the historical average. In the past eight years, EXEL's PE ratio was at its highest in the Mar 2017 quarter at 722.33, with a price of $21.67 and an EPS of $0.03. The Dec 2018 quarter recorded the bottom point at 8.48, with a price of $19.67 and an EPS of $2.32.
Exelixis PE ratio by year
Maximum annual increase: 235.44% in 2020
Maximum annual decrease: -85.49% in 2018
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 18.5 | -49.88% | $33.3 | $1.8 |
| 2023 | 36.91 | 31.17% | $23.99 | $0.65 |
| 2022 | 28.14 | 12.38% | $16.04 | $0.57 |
| 2021 | 25.04 | -55.09% | $18.28 | $0.73 |
| 2020 | 55.75 | 235.44% | $20.07 | $0.36 |
| 2019 | 16.62 | 95.99% | $17.62 | $1.06 |
| 2018 | 8.48 | -85.49% | $19.67 | $2.32 |
| 2017 | 58.46 | N/A | $30.4 | $0.52 |
| 2016 | N/A | N/A | $14.91 | -$0.28 |
| 2015 | N/A | N/A | $5.64 | -$0.77 |
| 2014 | N/A | N/A | $1.44 | -$1.34 |
| 2013 | N/A | N/A | $6.13 | -$1.33 |
| 2012 | N/A | N/A | $4.57 | -$0.92 |
| 2011 | 7.89 | N/A | $4.74 | $0.6 |
| 2010 | N/A | N/A | $8.21 | -$0.85 |
Exelixis PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | 18.5 | 12.67% | $33.3 | $1.8 |
| Sep 2024 | 16.42 | -14.52% | $25.95 | $1.58 |
| Jun 2024 | 19.21 | -48.19% | $22.47 | $1.17 |
| Mar 2024 | 37.08 | 0.46% | $23.73 | $0.64 |
| Dec 2023 | 36.91 | -52.7% | $23.99 | $0.65 |
| Sep 2023 | 78.04 | 108.27% | $21.85 | $0.28 |
| Jun 2023 | 37.47 | -7.34% | $19.11 | $0.51 |
| Mar 2023 | 40.44 | 43.71% | $19.41 | $0.48 |
| Dec 2022 | 28.14 | 72.32% | $16.04 | $0.57 |
| Sep 2022 | 16.33 | -33.32% | $15.68 | $0.96 |
| Jun 2022 | 24.49 | 1.53% | $20.82 | $0.85 |
| Mar 2022 | 24.12 | -3.67% | $22.67 | $0.94 |
| Dec 2021 | 25.04 | -37.23% | $18.28 | $0.73 |
| Sep 2021 | 39.89 | -32.13% | $21.14 | $0.53 |
| Jun 2021 | 58.77 | -42.76% | $18.22 | $0.31 |
EXEL average PE ratio chart
EXEL's current P/E ratio is lower than the 3, 5 and 10-year averages.
EXEL PE vs peers
EXEL's PE ratio is lower than its peer stocks JNJ and AMGN, but it is greater than MRK's and PFE's. Exelixis's current PE ratio of 20.58 is below the average of its peers, which is 24.23.
| Stock name | PE ratio | Market cap |
|---|---|---|
| MRK Merck & Co Inc | 12.83 | $219.1B |
| PFE Pfizer Inc | 17.34 | $139.53B |
| EXEL Exelixis Inc | 20.33 | $10.24B |
| JNJ Johnson & Johnson | 27.3 | $383.85B |
| AMGN Amgen Inc | 40.39 | $165.34B |
| BMY Bristol Myers Squibb Co | N/A | $119.4B |
| CRIS Curis Inc | N/A | $11.88M |
Frequently asked questions
What is Exelixis's PE ratio?
EXEL stock has a price to earnings ratio of 20.58 as of Apr 2, 2025.
What is the 3-year average PE ratio for Exelixis (EXEL)?
The 3-year average PE ratio for EXEL stock is 32.09.
What is the 5-year average PE ratio for Exelixis (EXEL)?
The 5-year average PE ratio for EXEL stock is 38.63.
What is the highest PE ratio for EXEL?
In the last eight years, the Mar 2017 quarter recorded the highest quarterly PE ratio at 722.33.
How does the current PE ratio for EXEL compare to its historical average?
EXEL's current price to earnings ratio is 63% below its 8-year historical average.
How is EXEL's PE ratio calculated (Exelixis PE ratio formula)?
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Apr 2, 2025), Exelixis's stock price is $37.04. The earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $1.8. Therefore, Exelixis's P/E ratio for today is 20.58. PE RATIO(20.58) = STOCK PRICE($37.04) / TTM EPS($1.8)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.